Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs XELOX in Elderly Adjuvant Colorectal Cancer
NCT06888843Phase 2Recruiting
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Nizhny Novgorod Regional Clinical Oncology Center. Primary endpoint: Disease Free Survival at 3 years. Started Feb 2025; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06888843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888843.